BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

October 27, 2026 | News

Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

October 26, 2026 | News

ESTEVE CDMO Invests Over $80 Million to Expand Pharmaceutical Manufacturing Capabilities in China

After more than two decades in China, ESTEVE CDMO marks a new chapter in its commitment to the country and the region. With more than $...

October 23, 2026 | News

Geneos Launches Global Phase 2 Trial of Personalised Cancer Vaccine to Prevent Liver Cancer Recurrence

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), a...

October 23, 2026 | News

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

October 22, 2026 | Analysis

CAS and Microsoft Bring Trusted Scientific Intelligence to Copilot to Accelerate Drug Discovery and R&D

CAS, a division of the American Chemical Society, announced the availability of CAS Connections in Microsoft Copilot. The connector gives Copilot customers...

October 22, 2026 | News

Insilico Medicine Hits First AI-Driven Oncology Milestone in $888 Million Servier Collaboration

Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reach...

October 22, 2026 | News

Metabolon Launches AI-Enabled Splash & Ripple to Accelerate Metabolomics-Driven Drug Discovery

New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpr...

October 22, 2026 | News

Ascletis Reports Promising Preclinical Data for Once-Weekly Oral Obesity Treatments, Advances US Phase 1 Trial

Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combina...

October 21, 2026 | News

PharmaEssentia Accelerates Global Expansion with US and Japan Drug Approvals and US$46 Million Manufacturing Investment

PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clini...

October 21, 2026 | News

Chipscreen Biosciences Secures China IND Approval for First-in-Class Cancer Immunotherapy NW001

Shenzhen Chipscreen Biosciences Co., Ltd. announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with ...

October 21, 2026 | News

The PD-(L)1 x VEGF Bispecific Race: Every APAC Programme in the Clinic, Counted

When the ESMO Congress opens in Madrid on 23 October, one drug class will be hard to miss. Two days in, on the evening of Sunday 25 October, the Presidenti...

October 16, 2026 | Analysis

Takeda’s First-in-Class Narcolepsy Drug ORZEYFUL Enters Japan and China Markets Following Regulatory Approvals

ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (...

October 16, 2026 | News

Danaher and NVIDIA Join Forces to Bring Autonomous AI-Powered Science into Laboratories

Danaher Corporation announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Da...

October 16, 2026 | News

Stay Connected